^
Association details:
| Biomarker: | CD8 overexpression |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
27P - Association between CD8+ tumor infiltrating lymphocytes and the clinical outcome of patients with operable breast cancer treated with adjuvant dose-dense chemotherapy. A 10 - year follow up report of a Hellenic Cooperative Oncology Group observational study
Published date:
05/03/2022
Excerpt:
We investigated the prognostic impact of CD8+ TILs in patients with early intermediate/high-risk breast cancer treated with adjuvant anthracycline-based chemotherapy....All patients received dose-dense sequential chemotherapy with E-T-CMF regimen....Patients with high intratumoral and total CD8 had longer DFS and OS as compared to those with low counts/mm2 (DFS: HR=0.58, p=0.011 and HR=0.65, p=0.034 and OS: HR=0.63, p=0.043 and HR=0.58, p=0.020, respectively)....CD8+ TILs and especially their intratumoral subset, represent a potential favorable prognostic factor and impact survival rates in early breast cancer.
